Francisco Gama

Francisco Gama

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2022 in JACC: Cardiovascular Imaging
Verified
Journal Article
Closed access
FGFrancisco Gama
Francisco Gama
SRStefania Rosmini
Stefania Rosmini
SBSteve Bandula
Steve Bandula
KPKush P. Patel
Kush P. Patel
PMPaolo Massa
Paolo Massa
TTThomas A Treibel
Thomas A Treibel

1 December 2024 in Circulation: Cardiovascular Imaging
Verified
Journal Article
Open access
JBJonathan Bennett
Jonathan Bennett
GTGeorge D. Thornton
George D. Thornton
CNChristian Nitsche
Christian Nitsche
FGFrancisco Gama
Francisco Gama
NANikoo Aziminia
Nikoo Aziminia
JYJohn Yap
John Yap
BACKGROUND: In aortic stenosis, the myocardium responds with left ventricular hypertrophy, which is characterized by increased left ventricular mass due to cellular hypertrophy and extracellular matrix expansion. Following aortic valve replacement (AVR), left ventricular hypertrophy regression occurs, but early cellular and extracellular dynamics are unknown. METHODS: Patients with severe symptomatic aortic stenosis undergoing surgical or transcatheter AVR were prospectively recruited. Pre- and early post-AVR cardiac magnetic resonance imaging assessed left ventricular remodeling, global longitudinal strain, and T1 mapping to determine extracellular volume fraction and volume of cellular and extracellular compartments. RESULTS: In all, 39 patients (aged 71.4±9.8 years, male 79%, aortic valve peak velocity 4.4±0.5 m/s) underwent cardiac magnetic resonance before and at median 7.7 weeks post-AVR. Left ventricular mass index reduced significantly by 15.4% ( P <0.001*), primarily driven by cellular compartment regression (18.7%, P <0.001*), with a smaller reduction in the extracellular compartment (7.2%, P <0.001*). This unbalanced regression led to an apparent increase in extracellular volume fraction (27.4±3.1% to 30.2±2.8%; P 0.05). The asterisk in P values indicates a statistical significance of <0.05. CONCLUSIONS: Within 8 weeks of AVR for aortic stenosis, substantial left ventricular hypertrophy regression occurs involving both cellular and extracellular compartments, demonstrating the early myocardial adaptability to afterload relief. Cellular compartment regression is greater than extracellular regression, leading to an apparent increase in extracellular volume fraction. Mode of intervention did not affect degree of reverse remodeling, indicating that both are effective at resulting beneficial changes post-AVR. REGISTRATION: URL: https://www.isrctn.com ; Unique identifier: NCT04627987.

14 August 2021 in The International Journal of Cardiovascular Imaging
Verified
Journal Article
Closed access
PDF file
FGFrancisco Gama
Francisco Gama
PGPedro de Araújo Gonçalves
Pedro de Araújo Gonçalves
JAJoão Abecasis
João Abecasis
AFAntónio Miguel Ferreira
António Miguel Ferreira
PFPedro Freitas
Pedro Freitas
RTRui Campante Teles
Rui Campante Teles

21 April 2020 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
FGFrancisco Gama
Francisco Gama
JFJorge Ferreira
Jorge Ferreira
JCJoão Carmo
João Carmo
FCFrancisco Costa
Francisco Costa
SCSalomé Carvalho
Salomé Carvalho
MMMiguel Mendes
Miguel Mendes
BACKGROUND: Medical therapy for heart failure with reduced ejection fraction evolved since trials validated the use of implantable cardioverter–defibrillators ( ICD s). We sought to evaluate the performance of ICD s in reducing mortality in the era of modern medical therapy by means of a systematic review and meta‐analysis of contemporary randomized clinical trials of drug therapy for heart failure with reduced ejection fraction. METHODS AND RESULTS: We systematically identified randomized clinical trials that evaluated drug therapy in patients with heart failure with reduced ejection fraction that reported mortality. Studies that enrolled 40%, or patients in the acute phase of heart failure and study treatment with devices were excluded. We identified 8 randomized clinical trials, including 31 701 patients of whom 3631 (11.5%) had an ICD . ICDs were associated with a lower risk of all‐cause mortality (relative risk [RR], 0.85; 95% CI, 0.78–0.94) and sudden cardiac death (RR, 0.49; 95% CI, 0.40–0.61). Results were consistent among studies published before and after 2010. In meta‐regression analysis, the proportion of nonischemic etiology did not affect the associated benefit of ICD . CONCLUSIONS: In our meta‐analysis of contemporary randomized trials of drug therapy for heart failure with reduced ejection fraction, the rate of ICD use was low and associated with a decreased risk in both all‐cause mortality and sudden cardiac death. This benefit was still present in trials with new medical therapy.

24 April 2024 in JACC: Cardiovascular Imaging
Verified
Journal Article
Closed access
GTGeorge D. Thornton
George D. Thornton
JBJonathan B. Bennett
Jonathan B. Bennett
CNChristian Nitsche
Christian Nitsche
FGFrancisco Gama
Francisco Gama
NANikoo Aziminia
Nikoo Aziminia
TTThomas A. Treibel
Thomas A. Treibel

20 March 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MPMariana Sousa Paiva
Mariana Sousa Paiva
FGFrancisco Gama
Francisco Gama
SCSamuel Azevedo Chaves
Samuel Azevedo Chaves
PLPedro M. Lopes
Pedro M. Lopes
FAFrancisco Albuquerque
Francisco Albuquerque
PAPedro Pulido Adragão
Pedro Pulido Adragão
Background and Aim: Left ventricular thrombus (LVT) is a common complication of myocardial infarction (MI) and heart failure with reduced ejection fraction (HFrEF), typically managed with vitamin K antagonists (VKAs) for up to six months. However, data on direct oral anticoagulants (DOACs) for LVT treatment remain limited and conflicting. This study evaluates the effectiveness and safety of DOACs compared to warfarin for LVT resolution. Methods: We conducted a single-center retrospective cohort study of consecutive patients diagnosed with LVT from January 2010 to May 2024. The primary outcome was LVT resolution at 24 months. Safety outcomes included major bleeding and thromboembolic events. Diagnosis and follow-up were performed via echocardiography, with cardiac magnetic resonance and computed tomography as needed. Anticoagulant type, dose, duration, and concurrent antiplatelet therapy were at the treating physician’s discretion. Results: Among 171 patients (82.5% male, mean age 59.8 ± 14.7 years), 99 received DOACs and 72 received warfarin. LVT resolution was higher with DOACs (66.7% vs. 50%, HR 2.0, 95% CI 1.07–3.73, p = 0.029), with a trend toward faster thrombus resolution (185 vs. 220 days, p = 0.214) though statistically not significant. DOAC use remained an independent predictor of LVT resolution, regardless of antiplatelet use. Major bleeding (2.9%), thromboembolic events (5.3%), and mortality (5.3%) were similar between groups. Conclusions: DOAC therapy was associated with higher LVT resolution rates and a comparable safety profile to warfarin. Further randomized clinical trials are warranted to validate these findings.